- Home
- RAPT vs ATAI Comparison
RAPT vs ATAI Comparison
Compare RAPT & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RAPT | ATAI |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | 60 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RAPT | ATAI |
|---|---|---|
| Price | $58.00 | $3.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 7 |
| Target Price | ★ $56.22 | $13.86 |
| AVG Volume (30 Days) | ★ 4.1M | 3.9M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $308,000.00 |
| Revenue This Year | N/A | $956.49 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.71 | $1.15 |
| 52 Week High | $57.99 | $6.73 |
Technical Indicators
Market Signals| Indicator | RAPT | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 78.59 | 45.85 |
| Support Level | $32.00 | $3.42 |
| Resistance Level | N/A | $4.28 |
| Average True Range (ATR) | 0.09 | 0.30 |
| MACD | -0.79 | -0.01 |
| Stochastic Oscillator | 95.31 | 24.06 |
Price Performance
Historical ComparisonAbout RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
About ATAI ATAI Life Sciences N.V.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.